PD-1/PD-L1
PD-1/Programmed death-ligand 1
Programmed death-1 (PD-1) is a cell surface receptor that functions as a T cell checkpoint and plays a central role in regulating T cell exhaustion. PD-1 is activated by the engagement of its ligands PDL-1 or PDL-2. PD-1 receptor delivers inhibitory checkpoint signals to activated T cells upon binding to its ligands PD-L1 and PD-L2 expressed on antigen-presenting cells and cancer cells, resulting in suppression of T-cell effector function and tumor immune evasion. Inhibiting the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway is an attractive strategy for tumor immunotherapy.
PD-1 is expressed on activated T cells, B cells, monocytes, dendritic cells (DCs), regulatory T cells (Tregs), and natural killer T cells (NKT). It is a member of a family of immunoglobulin domain (Ig) co-receptors that modify the outcome of activation of the T cell receptor by an antigen-presenting cell (APC) or infected target cell. PD-L1 is widely and constitutively expressed on both hematopoietic and nonhematopoietic cells; e.g., naive T and B cells, vascular endothelial cells, and pancreatic islet cells, whereas PD-L2 is exclusively and inducibly expressed on professional APCs.
All Product Categories
-
PD-1/PD-L1 Inhibitors
(341)
View all products
-
PD-1/PD-L1 Agonists
(5)
View all products
-
PD-1/PD-L1 Antagonists
(11)
View all products
-
PD-1/PD-L1 Activators
(16)
View all products
-
PD-1/PD-L1 Modulators
(7)
View all products
-
PD-1/PD-L1 Inducers
(3)
View all products
-
PD-1/PD-L1 Degraders
(13)
View all products
-
PD-1/PD-L1 Control
(1)
View all products
-
PD-1/PD-L1 Substrates
(2)
View all products
-
PD-1/PD-L1 Ligands
(7)
View all products
-
PD-1/PD-L1 Related Products (451)
Related Products (451)
-
Antibodies (8)
-
Lorigerlimab
0 ImagesCat. No.: HY-P99714CAS No.: 2416595-46-3Synonyms: MGD019
-
AUNP-12
0 ImagesSynonyms: NP-12AUNP-12 (NP-12) is a peptide antagonist of the PD-1 signaling pathway, displays equipotent antagonism toward PD-L1 and PD-L2 in rescue of lymphocyte proliferation and effector functions. AUNP-12 exhibits immune activation, excellent antitumor activity, and potential for better management of immune-related adverse events (irAEs).
-
Tagitanlimab
0 ImagesSynonyms: HBM-9167; KL-A167
-
Socazolimab
0 ImagesSynonyms: ZKAB001; STI-1014; STI-A1014Socazolimab (ZKAB001) is an anti-PD-L1 monoclonal antibody. Socazolimab has lasting safety and efficacy in the treatment of recurrent or metastatic cervical cancer. Socazolimab also has potential applications in small cell lung cancer, esophageal squamous cell carcinoma (ESCC), advanced urothelial carcinoma and osteosarcoma.
-
PD-1/PD-L1-IN-33
0 ImagesPD-1/PD-L1-IN-33 (Compound N11) is a PD-1/PD-L1 inhibitor. PD-1/PD-L1-IN-33 inhibits PD-1 and PD-L1 interaction with an IC50: 6.3 nM. PD-1/PD-L1-IN-33 promotes T-cell proliferation, activation, and infiltration into tumor spheres. PD-1/PD-L1-IN-33 has immunomodulatory and anticancer activity.
-
PD1-PDL1-IN 1 TFA
0 ImagesCat. No.: HY-101058APD1-PDL1-IN 1 TFA (compound 16) is a potent programmed cell death 1 (PD-1) inhibitor. PD1-PDL1-IN 1 TFA is useful as immune modulator.
-
Kaempferol-7-O-rhamnoside
0 ImagesKaempferol-7-O-rhamnoside is a PD-1/PD-L1 inhibitor and farnesoid X receptor (FXR) agonist. Kaempferol-7-O-rhamnoside demonstrates cardioprotective potential targeting the AMPKα1 signaling pathway. Kaempferol-7-O-rhamnoside significantly upregulates the mRNA expression of AMPKα1 in H9c2 cardiomyocytes. Kaempferol-7-O-rhamnoside reverses APAP-induced reduction of glutathione (GSH) content and increase of ROS production in L02 cells. Kaempferol-7-O-rhamnoside has the potential for heart failure.
-
Nofazinlimab
0 ImagesSynonyms: CS1003
-
GJ19
0 ImagesGJ19 is a PD-L1 inhibitor with an IC50 of 32.06 nM. GJ19 can effectively bind to human/murine PD-L1 protein with Kd values of 171 and 290 nM, respectively. GJ19 concentration-dependently promotes HepG2 cell mortality in a co-culture model of HepG2/hPD-L1 and Jurkat T/hPD-1 cells. GJ19 effectively suppresses tumor growth in a B16-F10 melanoma mouse model. GJ19 can be used for the study of tumor immunotherapy.
-
Latikafusp
0 ImagesCat. No.: HY-P99687CAS No.: 2552814-07-8Synonyms: AMG 256Latikafusp (AMG 256) is a bifunctional fusion protein comprising a PD-1-targeting antibody and IL-21 mutein designed to deliver IL-21 pathway stimulation to PD-1+ cells. Latikafusp is designed to prime and extend the activity of cytotoxic and memory T cells and induce anti-tumor immunity. Latikafusp has the potential for solid tumors research.Latikafusp may lead to the development of immunogenicity-mediated responses.
-
Sec61-IN-3
0 ImagesSec61-IN-3 is a Sec61 inhibitor. Sec61-IN-3 shows a significant inhibitory effect on PD-1 related reporter gene cell models (PD1tsGluc) (IC50 = 42 nM), and also has certain inhibitory activity on Her3 (IC50 = 99 nM), IL2 (IC50 = 144 nM) related reporter pathways, but has a relatively weak inhibitory effect on the TNFα (IC50 = 580 nM) pathway. Sec61-IN-3 can be used for cancer research.
-
PD-1/PD-L1-IN-23
0 ImagesPD-1/PD-L1-IN-23 is a potent and orally active inhibitor of PD-1/PD-L1. PD-1/PD-L1-IN-23 is an ester proagent of L7. L7 is a benzo[c][1,2,5]oxadiazole derivative and biologically evaluated as inhibitors of PD-L1. PD-1/PD-L1-IN-23 displays significant antitumor effects in tumor models of syngeneic and PD-L1 humanized mice.
-
Simridarlimab
0 ImagesSynonyms: IBI-322Simridarlimab (IBI-322) is a bispecific antibody targeting PD-L1 and CD47. Simridarlimab attenuates CD47 activity in monovalent binding and blockes PD-L1 activity in bivalent binding. Simridarlimab selectively binds to CD47+PD-L1+ tumor cells, effectively inhibits CD47-SIRPα signal and triggered strong tumor cell phagocytosis in vitro.
-
(D)-PPA 1 TFA
0 ImagesCat. No.: HY-P4072APurity: 99.11%(D)-PPA 1 TFA is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 TFA serves as a potent PD-1/PD-L1 inhibitor. (D)-PPA 1 TFA binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy.
-
Sasanlimab
0 ImagesSynonyms: PF-06801591Sasanlimab is a humanized IgG4 isotype anti-PD-1 antibody. Sasanlimab blocks PD-1 interaction with PD-L1/PD-L2, reverses PD-1-mediated inhibitory T-cell signaling, augments T-cell proliferation and cytokine production. Sasanlimab inhibits colon adenocarcinoma tumor growth, and accelerates graft-versus-host disease incidence via enhanced T-cell activity. Sasanlimab can be used for the research of cancer, such as bladder cancer and colon adenocarcinoma.
-
Reozalimab
0 ImagesSynonyms: LY3434172; IBI-318Reozalimab (LY3434172; IBI-318) is an IgG1 monoclonal antibody targeting PD-1/PD-L1, with an IC50 of 2.27 nM and an EC50 of 0.080 nM against human PD-1, as well as an IC50 of 0.75 nM and an EC50 of 0.455 nM against human PD-L1. Reozalimab blocks the binding of PD-1 to PD-L1/PD-L2, as well as the binding of PD-L1 to PD-1/CD80, thereby inhibiting the inhibitory signal transduction of the PD-1 pathway. Reozalimab enhances the functional activation of T cells and induces anti-tumor activity in mouse tumor models reconstituted with human immune cells. Reozalimab can be used in research related to cancers such as non-small cell lung cancer and ovarian cancer.
-
Anti-Mouse PD-1 (LALA-PG) Antibody (RMP1-14)
0 ImagesCat. No.: HY-P991078Purity: 98.83%
